Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM15275 in Type 2 Diabetes Mellitus
NCT07527650Phase 2Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efocipegtrutide in type 2 diabetes mellitus (T2DM), sponsored by Hanmi Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
efocipegtrutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07527650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527650.